Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer

Go back to Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
(NASDAQ: NTRA) Delayed: 324.35 -3.83 (1.17%)
Previous Close $328.18    52 Week High $13.80 
Open $326.29    52 Week Low $6.52 
Day High $328.54    P/E N/A 
Day Low $321.21    EPS $0.00 
Volume 160,171